PTC-028

PTC-028 is an orally bioavailable inhibitor of stem cell factor BMI-1 in ovarian cancer. PTC-028 selectively inhibits cancer cells whereas normal cells remain unaffected. PTC-028 downregulates BMI-1, inducing caspase-mediated apoptosis[1].

Product Specifications

CAS Number

[1782970-28-8]

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Apoptosis; BMI1

Type

Reference compound

Related Pathways

Apoptosis; Stem Cell/Wnt

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/ptc-028.html

Purity

98.0

Solubility

DMSO : 125 mg/mL (ultrasonic)

Smiles

FC(C1=CC=C(NC2=NC(N3C4=CC(F)=C(F)C=C4N=C3C)=CN=C2)C=C1)(F)F

Molecular Formula

C19H12F5N5

Molecular Weight

405.32

Precautions

H302, H315, H319, H335

References & Citations

[1]Dey A, et al. Evaluating the Mechanism and Therapeutic Potential of PTC-028, a Novel Inhibitor of BMI-1 Function in Ovarian Cancer. Mol Cancer Ther. 2018 Jan;17 (1) :39-49.